Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1036 to 1050 of 1285 results for social care

  1. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

    Technology appraisal guidance
    Published
    26 May 2010
    View recommendations

    Sections for TA188

  2. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

    Technology appraisal guidance
    Last updated
    15 January 2025
    View recommendations

    Sections for TA697

  3. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.

    HealthTech guidance
    Published
    9 May 2024
    View recommendations

    Sections for HTG719

  4. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

    Technology appraisal guidance
    Last updated
    29 August 2024
    View recommendations

    Sections for TA737

  7. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  8. Assessment of disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further refined and validated to: - assess disease severity and impact in both non-specialist and specialist healthcare settings, to facilitate assessment, appropriate referral, treatment planning and measurement of outcomes - measure burden and cumulative effect of disease activity, severity and impact for people with both psoriasis and psoriatic arthritis?

    disease severity and impact is fundamental to delivering high-quality health care and measuring outcomes. The evidence review indicates...

    Research recommendation
    Published
    9 June 2015

  9. Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.

    HealthTech guidance
    Published
    17 April 2025
    View recommendations

    Sections for HTG742

  10. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    for vulnerable groups.In the committee's experience, professionals such as care workers and health visitors, and the public, are...

    Research recommendation
    Published
    10 February 2020

  11. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

    HealthTech guidance
    Published
    21 October 2024
    View recommendations

    Sections for HTG729

  12. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  13. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

    NICE guideline
    Discontinued

  14. Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

    Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    1 June 2014
    View recommendations

    Sections for TA303

  15. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued Reference number: GID-TA10377

    Technology appraisal guidance
    Discontinued